Off target co-inhibition of AKR1C2 should be avoided in the context of prostate cancer, since AKR1C2 reduces the potent androgen, 5α-dihydrotestosterone.4 Similarly, off-target activation of ERα or AR is a particular concern for design of anticancer compounds based on steroidal scaffolds. Here, ESR1 is linked to prostate carcinoma.